Iron-deficiency Anemia Clinical Trial
Official title:
Use of Cast Iron Pots to Improve Maternal Anemia
NCT number | NCT02341300 |
Other study ID # | 1310014372 |
Secondary ID | |
Status | Terminated |
Phase | N/A |
First received | |
Last updated | |
Start date | July 15, 2020 |
Est. completion date | July 15, 2020 |
Verified date | July 2020 |
Source | Weill Medical College of Cornell University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Anemia of pregnancy is defined as a hemoglobin concentration of less than 11 g/dL in the
first and third trimesters, and less than 10.5 g/dL in the second trimester. The rates of
anemia are variable and depend largely on preexisting iron stores and supplementation.
Estimates from the World Health Organization report that 35% to 75% of pregnant women in
developing countries and 18% of women from industrialized countries are anemic. Maternal
anemia is associated with an increased risk of preterm birth, low birthweight, and small for
gestational age infants. Many studies have shown improvement in these outcomes with maternal
iron supplementation in cases of iron-deficiency anemia. Mounting evidence also indicates
that maternal iron deficiency in pregnancy reduces fetal iron stores, perhaps well into the
first year of life.
Anemia in pregnancy can also impact maternal morbidity and mortality. Viteri reported that
anemic pregnant women are at greater risk of death during the perinatal period and that
anemia is the major contributory or sole cause of death in 20-40% of the 500,000 maternal
deaths per year.
The need for iron averages close to 1000mg in a typical singleton gestation. This amount
considerably exceeds the iron stores of most women and will result in iron-deficiency anemia
unless supplemental iron is taken. One problem with iron supplement use is compliance,
secondary to adverse effects such as constipation and nausea. Research on the use of cast
iron pots in decreasing the incidence of iron-deficiency anemia in non-pregnant women has
been promising. These studies have demonstrated good compliance with no reported adverse
effects. The aim of our study is to determine if providing anemic women in the first
trimester of pregnancy with a cast iron pot will decrease the incidence of anemia later in
pregnancy.
Hypothesis: Cooking in cast iron pots will increase hematocrit levels in pregnancy.
Status | Terminated |
Enrollment | 34 |
Est. completion date | July 15, 2020 |
Est. primary completion date | July 15, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: - Pregnant women of any age in their first trimester of pregnancy with anemia defined as a Hemoglobin less than 11 and/or a hematocrit less than 33 - Willingness and ability to cook in provided cast iron pot at least 3x/week - Singleton gestations Exclusion Criteria: - Any secondary cause of anemia including inherited and acquired hemolytic anemias (sickle cell disease, thalessemia, malaria, etc) Inability or unwillingness to try to use cast iron pot approximately 3x/week - Women with severe chronic illness and high likelihood of preterm birth and/or expected long-term hospitalizations during pregnancy. Multifetal gestations |
Country | Name | City | State |
---|---|---|---|
United States | New York Prebyterian Hospital Weill Cornell | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Weill Medical College of Cornell University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Increased hematocrit in second and third trimesters of pregnancy | 28 weeks (2nd and 3rd trimesters of pregnancy) | ||
Secondary | Compliance assessment | We will assess compliance with iron/aluminium pot use at the conclusion of the study | postpartum, after ~30 weeks | |
Secondary | Incidence of adverse effects | Will contact patients to assess incidence of adverse effects of iron including constipation | Monthly phone surveys for 28 weeks | |
Secondary | Satisfaction | Will contact patient monthly to assess satisfaction with study intervention | Monthly phone surveys for 28 weeks | |
Secondary | Maternal anemia postpartum | Will assess subjects need for transfusion and/or symptoms of anemia (dizziness, lightheadedness) postpartum | postpartum, after ~30 weeks | |
Secondary | Neonatal outcomes | Will follow up neonatal outcomes to assess for prematurity and/or low birthweight | postpartum, at ~30 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04949165 -
Bloodsafe Ghana- Iron and Nutritional Counseling Strategy Pilot Study
|
N/A | |
Active, not recruiting |
NCT02541708 -
IV Ferric Carboxymaltose Compared With Oral Iron in the Treatment of Iron Deficiency Anemia at Delivery in Tanzania
|
Phase 3 | |
Completed |
NCT01942460 -
Ferumoxytol for Iron-Deficiency Anemia in Chronic Kidney Disease and Peritoneal Dialysis Patients
|
Phase 4 | |
Completed |
NCT00810030 -
FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR
|
Phase 3 | |
Completed |
NCT01047098 -
Effects of Taking Prenatal Vitamin-mineral Supplements During Lactation on Iron Status and Markers of Oxidation
|
N/A | |
Completed |
NCT00298051 -
Umbilical Cord Clamping and Infant Iron Status
|
N/A | |
Completed |
NCT01135576 -
Iron Fortified Beverages and Application in Women Predisposed to Anemia
|
N/A | |
Withdrawn |
NCT04320966 -
Neurovascular Complications and White Matter Damage in Acquired Anemias
|
||
Completed |
NCT01101399 -
Ferric Carboxymaltose in Subjects With Functional Iron Deficiency Undergoing Chemotherapy
|
Phase 3 | |
Completed |
NCT05240677 -
Endoscopy in CKD With Iron Deficiency Anemia
|
N/A | |
Terminated |
NCT01100879 -
Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy
|
Phase 4 | |
Recruiting |
NCT02487719 -
Different Iron Supplements for Prevention of Anemia in Pregnancy
|
Phase 4 | |
Recruiting |
NCT03232554 -
Buxue Yimu Pills for Gynecological Iron-Deficiency Anemia
|
Phase 2 | |
Completed |
NCT04318405 -
Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE).
|
||
Completed |
NCT02998697 -
Short Term Oral Iron Supplementation in Systolic Heart Failure Patients Suffering From Iron Deficiency Anemia
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT03411590 -
The Effect of Fortified Growing-up Milk on Growth and Micronutrient Status of Nigerian Toddlers
|
N/A | |
Completed |
NCT05365308 -
EHR-based Patient Identification and Panel Management of Patients With Iron Deficiency Anemia
|
N/A | |
Recruiting |
NCT01071759 -
Effects of Dietary Heme/Non-heme Iron and Helicobacter Pylori (Hp) Infection on Maternal Iron-deficiency Anemia and Fetal Growth Outcomes
|
N/A | |
Terminated |
NCT00882414 -
Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD)
|
Phase 2 | |
Completed |
NCT02968368 -
Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease
|
Phase 3 |